| pubmed-article:10856960 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10856960 | lifeskim:mentions | umls-concept:C0166049 | lld:lifeskim |
| pubmed-article:10856960 | lifeskim:mentions | umls-concept:C0206194 | lld:lifeskim |
| pubmed-article:10856960 | lifeskim:mentions | umls-concept:C0341439 | lld:lifeskim |
| pubmed-article:10856960 | lifeskim:mentions | umls-concept:C0033105 | lld:lifeskim |
| pubmed-article:10856960 | lifeskim:mentions | umls-concept:C1955852 | lld:lifeskim |
| pubmed-article:10856960 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10856960 | pubmed:dateCreated | 2000-7-18 | lld:pubmed |
| pubmed-article:10856960 | pubmed:abstractText | To investigate whether exposure to atomic bomb radiation altered the prevalence of hepatitis C virus (HCV) infection or accelerated the progress toward chronic hepatitis after HCV infection, the seropositivity of antibody to hepatitis C virus (anti-HCV) was determined for 6,121 participants in the Adult Health Study of atomic bomb survivors in Hiroshima and Nagasaki. The seropositivity of anti-HCV antibody was 2.5 times higher among those with a history of blood transfusion and 1.2 times higher among those with a family history of liver disease, whereas acupuncture showed no association with anti-HCV. Although the prevalence of anti-HCV was lower for survivors with positive dose estimates than for those with 0 dose (relative prevalence 0.84, P = 0.022), there was no evidence of a smooth dose-response relationship. However, these data suggested that the radiation dose response for chronic liver disease among HCV antibody-positive survivors may be greater than that among HCV antibody-negative survivors (slope ratio 20). In conclusion, no dose-response relationship was found between anti-HCV positivity and radiation dose; a possible increase in the radiation dose response of chronic liver disease among anti-HCV-positive individuals was found. Thus radiation exposure may accelerate the progress of chronic liver disease associated with hepatitis C virus infection. | lld:pubmed |
| pubmed-article:10856960 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10856960 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10856960 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10856960 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10856960 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10856960 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10856960 | pubmed:issn | 0033-7587 | lld:pubmed |
| pubmed-article:10856960 | pubmed:author | pubmed-author:KodamaKK | lld:pubmed |
| pubmed-article:10856960 | pubmed:author | pubmed-author:FujiwaraSS | lld:pubmed |
| pubmed-article:10856960 | pubmed:author | pubmed-author:YoshizawaHH | lld:pubmed |
| pubmed-article:10856960 | pubmed:author | pubmed-author:AkahoshiMM | lld:pubmed |
| pubmed-article:10856960 | pubmed:author | pubmed-author:KusumiSS | lld:pubmed |
| pubmed-article:10856960 | pubmed:author | pubmed-author:CologneJJ | lld:pubmed |
| pubmed-article:10856960 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10856960 | pubmed:volume | 154 | lld:pubmed |
| pubmed-article:10856960 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10856960 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10856960 | pubmed:pagination | 12-9 | lld:pubmed |
| pubmed-article:10856960 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:meshHeading | pubmed-meshheading:10856960... | lld:pubmed |
| pubmed-article:10856960 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10856960 | pubmed:articleTitle | Prevalence of anti-hepatitis C virus antibody and chronic liver disease among atomic bomb survivors. | lld:pubmed |
| pubmed-article:10856960 | pubmed:affiliation | Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan. | lld:pubmed |
| pubmed-article:10856960 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10856960 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:10856960 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10856960 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10856960 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10856960 | lld:pubmed |
